Nexilico, a leader in microbiome engineering and a PreMiEr industry partner, has recently initiated a Microbial Consortia Discovery Program to address health challenges associated with hepatic encephalopathy affecting liver patients. This is the company’s third discovery program that uses proprietary AI models to conduct millions of virtual experiments which then provide data on how microbial communities respond to various interventions. Nexilico will rely on PreMiEr testbeds and experimental data to inform the program. For additional details please read the press release here.
